OscoTech to Receive $5.1M Milestone from Yuhan's European Commercialization of EGFR Cancer Drug
OscoTech to receive $5.1M (approx. ₩7.6B, exchange rate ₩1,495.10) from Yuhan's European commercialization milestone from Janssen Biotech
Genosco to receive identical $5.1M (approx. ₩7.6B) distribution
Milestone from July 2015 EGFR targeted anticancer drug technology transfer agreement
Amounts to ~10.1% of OscoTech's latest standalone revenue (₩75.5B)
Payment due within 3 months of Yuhan's receipt of milestone
KOSDAQ Filing Information
Filing: Major Management Matters Related to Investment Decision (Distribution of Milestones from Yuhan Corporation's Janssen Biotech Technology Transfer)